Bibliographic Details
| Title: |
Clinical value of botulinum toxin in neurological indications. |
| Authors: |
Ward, A. B., Molenaers, G., Colosimo, C., Berardelli, A. |
| Source: |
European Journal of Neurology. Dec2006 Supplement, Vol. 13, p20-26. 7p. 1 Diagram, 1 Chart, 2 Graphs. |
| Subjects: |
Botulinum toxin, Acetylcholine, Disease management, Movement disorders, Cerebral palsy |
| Abstract: |
Botulinum toxin type-A (BoNT-A) prevents the release of acetylcholine at cholinergic junctions, thereby causing temporary muscle weakness lasting 3–4 months. It is now widely used to treat a broad range of clinical disorders characterized by muscle hyperactivity. BoNT-A has proved effective in the management of several neurological conditions and, in particular, in the management of movement disorders (e.g. blepharospasm, cervical dystonia, laryngeal dystonia, limb dystonia, hemifacial spasm, focal tics, tremor and other hyperkinetic disorders). As a treatment of spasticity, BoNT-A can improve mobility and dexterity as well as preventing the development of distressing and costly secondary complications. In cerebral palsy, BoNT-A is of value, being able to delay or even avoid surgery until motion patterns have become established. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Psychology and Behavioral Sciences Collection |
